From the Swiss Paraplegic Research, Nottwil, Switzerland (GM, MWGB); Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland (GM, IE-H, MWGB); Swiss Paraplegic Centre, Nottwil, Switzerland (IE-H); REHAB Basel, Basel, Switzerland (MH-G); Clinique Romande de Réadaptation, Sion, Switzerland (XJ); Spinal Cord Injury Center, Balgrist University Hospital, Zurich, Switzerland (MS); and Corporate Health Consulting, Düdingen, Switzerland (SB); and General practitioner practice, Schenkon, Switzerland (CW).
Am J Phys Med Rehabil. 2024 Nov 1;103(11S Suppl 3):S333-S340. doi: 10.1097/PHM.0000000000002562. Epub 2024 Jun 21.
The aim of the study is to provide a population-based evaluation of vaccination coverage to prevent respiratory complications from SARS-COV-2, influenza, and pneumococcus, among community-dwelling persons with spinal cord injury/disease.
This is a cross-sectional survey conducted in 2022, utilizing questionnaires administered to persons with spinal cord injury/disease living in Switzerland. Main outcomes were ever-vaccination rates for SARS-COV-2, influenza, and pneumococcus. Secondary outcomes included demographics, lesion and education levels, as well as respiratory and cardiovascular conditions. Vaccine hesitancy was additionally assessed for all three vaccines in nonvaccinated persons through questions on reasons for not getting vaccinated.
A total of 1158 persons participated in this survey. Overall vaccination rates were highest for SARS-COV-2 86.5% (95% CI = 84.4-88.3), followed by influenza 44.6 (41.7-47.6) and pneumococcus: 7.5% (6.0-9.3). The most prominent reasons for not being vaccinated were doubt on effectiveness (72.7%) and potential side effects (60%) for SARS-COV-2, patients did not feel at risk for influenza (57%) and insufficient information from the physician (52.4%) for pneumococcus vaccination.
In individuals with spinal cord injury/disease, vaccination coverage is notably low for influenza and especially pneumococcus. Vaccine hesitancy varies between vaccination types and is associated with vaccine-specific reasons. These findings underscore the imperative for updated clinical vaccination guidelines, improved public health information, and targeted intervention programs for specific patient groups.
本研究旨在评估社区居住的脊髓损伤/疾病患者预防 SARS-CoV-2、流感和肺炎球菌引起的呼吸道并发症的疫苗接种覆盖率。
这是一项 2022 年进行的横断面调查,利用问卷对居住在瑞士的脊髓损伤/疾病患者进行调查。主要结局为 SARS-CoV-2、流感和肺炎球菌的既往疫苗接种率。次要结局包括人口统计学、损伤和教育水平,以及呼吸道和心血管状况。对于未接种疫苗的人,还通过询问未接种疫苗的原因,评估了对所有三种疫苗的疫苗犹豫情况。
共有 1158 人参与了这项调查。总体疫苗接种率最高的是 SARS-CoV-2(86.5%(95%CI=84.4-88.3),其次是流感(44.6%(41.7-47.6)和肺炎球菌:7.5%(6.0-9.3)。未接种疫苗的最主要原因是对 SARS-CoV-2 的有效性(72.7%)和潜在副作用(60%)的怀疑,流感疫苗(57%)患者认为自己没有感染流感的风险,以及医生提供的信息不足(52.4%)。
在脊髓损伤/疾病患者中,流感和肺炎球菌的疫苗接种覆盖率明显较低。疫苗犹豫情况在不同疫苗类型之间存在差异,且与疫苗特异性原因相关。这些发现强调了更新临床疫苗接种指南、改善公共卫生信息以及针对特定患者群体实施针对性干预计划的必要性。